Recent success in gene replacement therapy for RPE65 on patients with LCA resulting in slight improvement of vision has opened the possibility and holds promise as potential treatment modality for retinal dystrophies in the future [22–25]. This evidence concerns the gene RPE65 and Leber congenital amaurosis.